Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Oaknin, A. Tinker, A.V. Gilbert, L. Samouëlian, V. Mathews, C. Brown, J. Barretina-Ginesta, M.-. Moreno, V. Gravina, A. Abdeddaim, C. Banerjee, S. Guo, W. Danaee, H. Im, E. Sabatier, R. (2021). Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Future oncology, Vol.17 (29), pp. 3781-3785.  show abstract

Banerjee, S. Lim, K.H. Murali, K. Kamposioras, K. Punie, K. Oing, C. O'Connor, M. Thorne, E. Devnani, B. Lambertini, M. Westphalen, C.B. Garrido, P. Amaral, T. Morgan, G. Haanen, J.B. Hardy, C. (2021). The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. Esmo open, Vol.6 (2), pp. 100058-100058.

Friedlander, M. Benson, C. O'Connell, R.L. Reed, N. Clamp, A. Lord, R. Millan, D. Nottley, S. Amant, F. Steer, C. Anand, A. Mileshkin, L. Beale, P. Banerjee, S. Bradshaw, N. Kelly, C. Carty, K. Divers, L. Alexander, L. Edmondson, R. (2021). Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic oncology, Vol.161 (1), pp. 160-165.

Foo, T. George, A. Banerjee, S. (2021). PARP inhibitors in ovarian cancer: An overview of the practice‐changing trials. Genes, chromosomes and cancer, Vol.60 (5), pp. 385-397.

Friedlander, M. Moore, K.N. Colombo, N. Scambia, G. Kim, B.-. Oaknin, A. Lisyanskaya, A. Sonke, G.S. Gourley, C. Banerjee, S. Oza, A. González-Martín, A. Aghajanian, C. Bradley, W.H. Liu, J. Mathews, C. Selle, F. Lortholary, A. Lowe, E.S. Hettle, R. Flood, E. Parkhomenko, E. DiSilvestro, P. (2021). Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. The lancet oncology, Vol.22 (5), pp. 632-642.

Moore, K.N. Oza, A.M. Colombo, N. Oaknin, A. Scambia, G. Lorusso, D. Konecny, G.E. Banerjee, S. Murphy, C.G. Tanyi, J.L. Hirte, H. Konner, J.A. Lim, P.C. Prasad-Hayes, M. Monk, B.J. Pautier, P. Wang, J. Berkenblit, A. Vergote, I. Birrer, M.J. (2021). Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Annals of oncology, Vol.32 (6), pp. 757-765.

Garrido, P. Adjei, A.A. Bajpai, J. Banerjee, S. Berghoff, A.S. Choo, S.P. Felip, E. Furness, A.J. Garralda, E. Haanen, J. Letsch, A. Linardou, H. Peters, S. Sessa, C. Tabernero, J. Tsang, J. Yang, J.C. Garassino, M.C. (2021). Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. Esmo open, Vol.6 (3), pp. 100131-100131.

An, D. Banerjee, S. Lee, J.-. (2021). Recent advancements of antiangiogenic combination therapies in ovarian cancer. Cancer treatment reviews, Vol.98, pp. 102224-102224.

Clamp, A.R. Lorusso, D. Oza, A.M. Aghajanian, C. Oaknin, A. Dean, A. Colombo, N. Weberpals, J.I. Scambia, G. Leary, A. Holloway, R.W. Amenedo Gancedo, M. Fong, P.C. Goh, J.C. O’Malley, D.M. Armstrong, D.K. Banerjee, S. García-Donas, J. Swisher, E.M. Cameron, T. Goble, S. Coleman, R.L. Ledermann, J.A. (2021). Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. International journal of gynecologic cancer, Vol.31 (7), pp. 949-958.  show abstract

Pujade-Lauraine, E. Fujiwara, K. Ledermann, J.A. Oza, A.M. Kristeleit, R. Ray-Coquard, I.-. Richardson, G.E. Sessa, C. Yonemori, K. Banerjee, S. Leary, A. Tinker, A.V. Jung, K.H. Madry, R. Park, S.-. Anderson, C.K. Zohren, F. Stewart, R.A. Wei, C. Dychter, S.S. Monk, B.J. (2021). Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. The lancet oncology, Vol.22 (7), pp. 1034-1046.

Lidington, E. Darlington, A.S. Vlooswijk, C. Beardsworth, S. McCaffrey, S. Tang, S. Stallard, K. Younger, E. Edwards, P. Ali, A.I. Nandhabalan, M. Din, A. Starling, N. Larkin, J. Stanway, S. Nobbenhuis, M. Banerjee, S. Szucs, Z. Gonzalez, M. Sirohi, B. Husson, O. van der Graaf, W.T. (2021). Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25–39 Years Old in the UK National Health Service. Clinical oncology, Vol.33 (8), pp. 494-506.

Au, L. Fendler, A. Shepherd, S.T. Rzeniewicz, K. Cerrone, M. Byrne, F. Carlyle, E. Edmonds, K. Del Rosario, L. Shon, J. Haynes, W.A. Ward, B. Shum, B. Gordon, W. Gerard, C.L. Xie, W. Joharatnam-Hogan, N. Young, K. Pickering, L. Furness, A.J. Larkin, J. Harvey, R. Kassiotis, G. Gandhi, S. Kassiotis, G. Gandhi, S. Swanton, C. Swanton, C. Fribbens, C. Wilkinson, K.A. Wilkinson, R.J. Lau, D.K. Banerjee, S. Starling, N. Chau, I. Au, L. Fendler, A. Shepherd, S.T. Byrne, F. Shum, B. Gerard, C. Young, K. Pickering, L. Furness, A.J. Larkin, J. Kassiotis, G. Wilkinson, K.A. Wilkinson, R.J. Banerjee, S. Starling, N. Chau, I. Turajlic, S. Turajlic, S. (2021). Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nature medicine, Vol.27 (8), pp. 1362-1366.  show abstract

Lim, K.H. Murali, K. Kamposioras, K. Punie, K. Oing, C. O’Connor, M. Thorne, E. Amaral, T. Garrido, P. Lambertini, M. Devnani, B. Westphalen, C.B. Morgan, G. Haanen, J.B. Hardy, C. Banerjee, S. (2021). The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II. Esmo open, Vol.6 (4), pp. 100199-100199.

Lidington, E. Vlooswijk, C. Stallard, K. Travis, E. Younger, E. Edwards, P. Nandhabalan, M. Hunter, N. Sarpal, N. Flett, D. Din, A. Starling, N. Larkin, J. Stanway, S. Nobbenhuis, M. Banerjee, S. Szucs, Z. Darlington, A. Gonzalez, M. Sirohi, B. Graaf, W.T. Husson, O. (2021). ‘This is not part of my life plan’: A qualitative study on the psychosocial experiences and practical challenges in young adults with cancer age 25 to 39 years at diagnosis. European journal of cancer care, Vol.30 (5).

Lima, J. Ali, Z. Banerjee, S. (2021). Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers. Clinical oncology, Vol.33 (9), pp. 608-615.

Vanacker, H. Harter, P. Labidi-Galy, S.I. Banerjee, S. Oaknin, A. Lorusso, D. Ray-Coquard, I. (2021). PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. Cancer treatment reviews, Vol.99, pp. 102255-102255.

Oaknin, A. Oza, A.M. Lorusso, D. Aghajanian, C. Dean, A. Colombo, N. Weberpals, J.I. Clamp, A.R. Scambia, G. Leary, A. Holloway, R.W. Amenedo Gancedo, M. Fong, P.C. Goh, J.C. O’Malley, D.M. Armstrong, D.K. Banerjee, S. García‐Donas, J. Swisher, E.M. Cameron, T. Maloney, L. Goble, S. Ledermann, J.A. Coleman, R.L. (2021). Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety. Cancer medicine, Vol.10 (20), pp. 7162-7173.

Chazan, G. Franchini, F. Alexander, M. Banerjee, S. Mileshkin, L. Blinman, P. Zielinski, R. Karikios, D. Pavlakis, N. Peters, S. Lordick, F. Ball, D. Wright, G. IJzerman, M. Solomon, B.J. (2021). Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians. Esmo open, Vol.6 (5), pp. 100224-100224.

Colombo, N. Moore, K. Scambia, G. Oaknin, A. Friedlander, M. Lisyanskaya, A. Floquet, A. Leary, A. Sonke, G.S. Gourley, C. Banerjee, S. Oza, A. González-Martín, A. Aghajanian, C. Bradley, W.H. Kim, J.-. Mathews, C. Liu, J. Lowe, E.S. Bloomfield, R. DiSilvestro, P. (2021). Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecologic oncology, Vol.163 (1), pp. 41-49.

Castelo-Branco, L. Awada, A. Pentheroudakis, G. Perez-Gracia, J.L. Mateo, J. Curigliano, G. Banerjee, S. Giuliani, R. Lordick, F. Cervantes, A. Tabernero, J. Peters, S. (2021). Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. Esmo open, Vol.6 (5), pp. 100237-100237.

Edmondson, R.J. O'Connell, R.L. Banerjee, S. Mileshkin, L. Sykes, P. Beale, P. Fisher, A. Bonaventura, A. Millan, D. Nottley, S. Benson, C. Hamilton, A. Sjoquist, K. Alexander, L. Kelly, C. Carty, K. Divers, L. Bradshaw, N. Friedlander, M. (2021). Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic oncology, Vol.163 (3), pp. 524-530.

Banerjee, S. Moore, K.N. Colombo, N. Scambia, G. Kim, B.-. Oaknin, A. Friedlander, M. Lisyanskaya, A. Floquet, A. Leary, A. Sonke, G.S. Gourley, C. Oza, A. González-Martín, A. Aghajanian, C. Bradley, W.H. Holmes, E. Lowe, E.S. DiSilvestro, P. (2021). Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet oncology, Vol.22 (12), pp. 1721-1731.

Khalique, S. Pettitt, S.J. Kelly, G. Tunariu, N. Natrajan, R. Banerjee, S. Lord, C.J. (2020). Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR. The journal of pathology: clinical research, Vol.6 (1), pp. 3-11.

Tischkowitz, M. Huang, S. Banerjee, S. Hague, J. Hendricks, W.P. Huntsman, D.G. Lang, J.D. Orlando, K.A. Oza, A.M. Pautier, P. Ray-Coquard, I. Trent, J.M. Witcher, M. Witkowski, L. McCluggage, W.G. Levine, D.A. Foulkes, W.D. Weissman, B.E. (2020). Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines. Clinical cancer research, Vol.26 (15), pp. 3908-3917.

Oza, A.M. Matulonis, U.A. Alvarez Secord, A. Nemunaitis, J. Roman, L.D. Blagden, S.P. Banerjee, S. McGuire, W.P. Ghamande, S. Birrer, M.J. Fleming, G.F. Markham, M.J. Hirte, H.W. Provencher, D.M. Basu, B. Kristeleit, R. Armstrong, D.K. Schwartz, B. Braly, P. Hall, G.D. Nephew, K.P. Jueliger, S. Oganesian, A. Naim, S. Hao, Y. Keer, H. Azab, M. Matei, D. (2020). A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clinical cancer research, Vol.26 (5), pp. 1009-1016.

Oaknin, A. Tinker, A.V. Gilbert, L. Samouëlian, V. Mathews, C. Brown, J. Barretina-Ginesta, M.-. Moreno, V. Gravina, A. Abdeddaim, C. Banerjee, S. Guo, W. Danaee, H. Im, E. Sabatier, R. (2020). Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer. Jama oncology, Vol.6 (11), pp. 1766-1766.

Banerjee, S. Tovey, H. Bowen, R. Folkerd, E. Kilburn, L. McLachlan, J. Hall, M. Tunariu, N. Attygalle, A. Lima, J.P. Perry, S. Chatfield, P. Hills, M. Kaye, S. Attard, G. Dowsett, M. Bliss, J.M. (2020). Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037). Therapeutic advances in medical oncology, Vol.12, pp. 175883592097535-175883592097535.  show abstract

Morgan, R.D. Banerjee, S. Hall, M. Clamp, A.R. Zhou, C. Hasan, J. Orbegoso, C. Taylor, S. Tugwood, J. Lyon, A.R. Dive, C. Rustin, G.J. Jayson, G.C. (2020). Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecologic oncology, Vol.156 (3), pp. 545-551.

Khalique, S. Lord, C.J. Banerjee, S. Natrajan, R. (2020). Translational genomics of ovarian clear cell carcinoma. Seminars in cancer biology, Vol.61, pp. 121-131.

Banerjee, S. Davidson, R. McLaurin, K. Sawyer, W. Long, G.H. (2020). Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data. Future oncology, Vol.16 (11), pp. 643-654.  show abstract

Ledermann, J.A. Oza, A.M. Lorusso, D. Aghajanian, C. Oaknin, A. Dean, A. Colombo, N. Weberpals, J.I. Clamp, A.R. Scambia, G. Leary, A. Holloway, R.W. Gancedo, M.A. Fong, P.C. Goh, J.C. O'Malley, D.M. Armstrong, D.K. Banerjee, S. García-Donas, J. Swisher, E.M. Cameron, T. Maloney, L. Goble, S. Coleman, R.L. (2020). Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. The lancet oncology, Vol.21 (5), pp. 710-722.

Scaranti, M. Cojocaru, E. Banerjee, S. Banerji, U. (2020). Exploiting the folate receptor α in oncology. Nature reviews clinical oncology, Vol.17 (6), pp. 349-359.

Millstein, J. Budden, T. Goode, E.L. Anglesio, M.S. Talhouk, A. Intermaggio, M.P. Leong, H.S. Chen, S. Elatre, W. Gilks, B. Nazeran, T. Volchek, M. Bentley, R.C. Wang, C. Chiu, D.S. Kommoss, S. Leung, S.C. Senz, J. Lum, A. Chow, V. Sudderuddin, H. Mackenzie, R. George, J. Fereday, S. Hendley, J. Traficante, N. Steed, H. Koziak, J.M. Köbel, M. McNeish, I.A. Goranova, T. Ennis, D. Macintyre, G. Silva De Silva, D. Ramón y Cajal, T. García-Donas, J. Hernando Polo, S. Rodriguez, G.C. Cushing-Haugen, K.L. Harris, H.R. Greene, C.S. Zelaya, R.A. Behrens, S. Fortner, R.T. Sinn, P. Herpel, E. Lester, J. Lubiński, J. Oszurek, O. Tołoczko, A. Cybulski, C. Menkiszak, J. Pearce, C.L. Pike, M.C. Tseng, C. Alsop, J. Rhenius, V. Song, H. Jimenez-Linan, M. Piskorz, A.M. Gentry-Maharaj, A. Karpinskyj, C. Widschwendter, M. Singh, N. Kennedy, C.J. Sharma, R. Harnett, P.R. Gao, B. Johnatty, S.E. Sayer, R. Boros, J. Winham, S.J. Keeney, G.L. Kaufmann, S.H. Larson, M.C. Luk, H. Hernandez, B.Y. Thompson, P.J. Wilkens, L.R. Carney, M.E. Trabert, B. Lissowska, J. Brinton, L. Sherman, M.E. Bodelon, C. Hinsley, S. Lewsley, L.A. Glasspool, R. Banerjee, S.N. Stronach, E.A. Haluska, P. Ray-Coquard, I. Mahner, S. Winterhoff, B. Slamon, D. Levine, D.A. Kelemen, L.E. Benitez, J. Chang-Claude, J. Gronwald, J. Wu, A.H. Menon, U. Goodman, M.T. Schildkraut, J.M. Wentzensen, N. Brown, R. Berchuck, A. Chenevix-Trench, G. deFazio, A. Gayther, S.A. García, M.J. Henderson, M.J. Rossing, M.A. Beeghly-Fadiel, A. Fasching, P.A. Orsulic, S. Karlan, B.Y. Konecny, G.E. Huntsman, D.G. Bowtell, D.D. Brenton, J.D. Doherty, J.A. Pharoah, P.D. Ramus, S.J. Bowtell, D. Chenevix-Trench, G. Green, A. Webb, P. DeFazio, A. Gertig, D. Traficante, N. Fereday, S. Moore, S. Hung, J. Harrap, K. Sadkowsky, T. Pandeya, N. Malt, M. Mellon, A. Robertson, R. Vanden Bergh, T. Jones, M. Mackenzie, P. Maidens, J. Nattress, K. Chiew, Y.E. Stenlake, A. Sullivan, H. Alexander, B. Ashover, P. Brown, S. Corrish, T. Green, L. Jackman, L. Ferguson, K. Martin, K. Martyn, A. Ranieri, B. White, J. Jayde, V. Mamers, P. Bowes, L. Galletta, L. Giles, D. Hendley, J. Alsop, K. Schmidt, T. Shirley, H. Ball, C. Young, C. Viduka, S. Tran, H. Bilic, S. Glavinas, L. Brooks, J. Stuart-Harris, R. Kirsten, F. Rutovitz, J. Clingan, P. Glasgow, A. Proietto, A. Braye, S. Otton, G. Shannon, J. Bonaventura, T. Stewart, J. Begbie, S. Friedlander, M. Bell, D. Baron-Hay, S. Ferrier,a, A. Gard, G. Nevell, D. Pavlakis, N. Valmadre, S. Young, B. Camaris, C. Crouch, R. Edwards, L. Hacker, N. Marsden, D. Robertson, G. Beale, P. Beith, J. Carter, J. Dalrymple, C. Houghton, R. Russell, P. Links, M. Grygiel, J. Hill, J. Brand, A. Byth, K. Jaworski, R. Harnett, P. Sharma, R. Wain, G. Ward, B. Papadimos, D. Crandon, A. Cummings, M. Horwood, K. Obermair, A. Perrin, L. Wyld, D. Nicklin, J. Davy, M. Oehler, M.K. Hall, C. Dodd, T. Healy, T. Pittman, K. Henderson, D. Miller, J. Pierdes, J. Blomfield, P. Challis, D. McIntosh, R. Parker, A. Brown, B. Rome, R. Allen, D. Grant, P. Hyde, S. Laurie, R. Robbie, M. Healy, D. Jobling, T. Manolitsas, T. McNealage, J. Rogers, P. Susil, B. Sumithran, E. Simpson, I. Phillips, K. Rischin, D. Fox, S. Johnson, D. Lade, S. Loughrey, M. O’Callaghan, N. Murray, W. Waring, P. Billson, V. Pyman, J. Neesham, D. Quinn, M. Underhill, C. Bell, R. Ng, L.F. Blum, R. Ganju, V. Hammond, I. Leung, Y. McCartney, A. Buck, M. Haviv, I. Purdie, D. Whiteman, D. Zeps, N. (2020). Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of oncology, Vol.31 (9), pp. 1240-1250.

Monk, B.J. Grisham, R.N. Banerjee, S. Kalbacher, E. Mirza, M.R. Romero, I. Vuylsteke, P. Coleman, R.L. Hilpert, F. Oza, A.M. Westermann, A. Oehler, M.K. Pignata, S. Aghajanian, C. Colombo, N. Drill, E. Cibula, D. Moore, K.N. Christy-Bittel, J. del Campo, J.M. Berger, R. Marth, C. Sehouli, J. O’Malley, D.M. Churruca, C. Boyd, A.P. Kristensen, G. Clamp, A. Ray-Coquard, I. Vergote, I. (2020). MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Journal of clinical oncology, Vol.38 (32), pp. 3753-3762.  show abstract

Colombo, N. Oza, A.M. Lorusso, D. Aghajanian, C. Oaknin, A. Dean, A. Weberpals, J.I. Clamp, A.R. Scambia, G. Leary, A. Holloway, R.W. Gancedo, M.A. Fong, P.C. Goh, J.C. O'Malley, D.M. Armstrong, D.K. Banerjee, S. García-Donas, J. Swisher, E.M. Meunier, J. Cameron, T. Maloney, L. Goble, S. Bedel, J. Ledermann, J.A. Coleman, R.L. (2020). The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. Gynecologic oncology, Vol.159 (1), pp. 101-111.

Curigliano, G. Banerjee, S. Cervantes, A. Garassino, M.C. Garrido, P. Girard, N. Haanen, J. Jordan, K. Lordick, F. Machiels, J.P. Michielin, O. Peters, S. Tabernero, J. Douillard, J.Y. Pentheroudakis, G. Addeo, A. Albiges, L. Ascierto, P.A. Banerjee, S. Barlesi, F. Caldas, C. Cardoso, F. Cervantes, A. Chaberny, I.F. Cherny, N.I. Choueiri, T.K. Chua, M.L. Criscitiello, C. Curigliano, G. de Azambuja, E. De Ruysscher, D. de Vries, E. Dent, R. Douillard, J.Y. D’Ugo, D. Dziadziuszko, R. Faivre-Finn, C. Felip, E. Garassino, M. Garrido, P. Girard, N. Glynne-Jones, R. Golfinopoulos, V. Haanen, J. Hamilton, E. Jänne, P.A. Jordan, K. Kanesvaran, R. Kim, S.B. Liebert, U.G. Lordick, F. Machiels, J.P. Michielin, O. Mok, T.S. Morgan, G. Obermannova, R. Park, K. Passaro, A. Pentheroudakis, G. Peters, S. Reck, M. Salazar Soler, R. Scotté, F. Senan, S. Sessa, C. Smyth, E. Soo, R. Soria, J.C. Spicer, J. Strasser, F. Tabernero, J. Tan, D.S. Trapani, D. Van Cutsem, E. van Halteren, H. van Schil, P.E. Veronesi, G. Yang, J. (2020). Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Annals of oncology, Vol.31 (10), pp. 1320-1335.

Hall, M.R. Dehbi, H.-. Banerjee, S. Lord, R. Clamp, A. Ledermann, J.A. Nicum, S. Lilleywhite, R. Bowen, R. Michael, A. Feeney, A. Glasspool, R. Hackshaw, A. Rustin, G. (2020). A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer. Gynecologic oncology, Vol.159 (3), pp. 692-698.

Talhouk, A. George, J. Wang, C. Budden, T. Tan, T.Z. Chiu, D.S. Kommoss, S. Leong, H.S. Chen, S. Intermaggio, M.P. Gilks, B. Nazeran, T.M. Volchek, M. Elatre, W. Bentley, R.C. Senz, J. Lum, A. Chow, V. Sudderuddin, H. Mackenzie, R. Leong, S.C. Liu, G. Johnson, D. Chen, B. Group, A.O. Alsop, J. Banerjee, S.N. Behrens, S. Bodelon, C. Brand, A.H. Brinton, L. Carney, M.E. Chiew, Y.-. Cushing-Haugen, K.L. Cybulski, C. Ennis, D. Fereday, S. Fortner, R.T. García-Donas, J. Gentry-Maharaj, A. Glasspool, R. Goranova, T. Greene, C.S. Haluska, P. Harris, H.R. Hendley, J. Hernandez, B.Y. Herpel, E. Jimenez-Linan, M. Karpinskyj, C. Kaufmann, S.H. Keeney, G.L. Kennedy, C.J. Köbel, M. Koziak, J.M. Larson, M.C. Lester, J. Lewsley, L.-. Lissowska, J. Lubiński, J. Luk, H. Macintyre, G. Mahner, S. McNeish, I.A. Menkiszak, J. Nevins, N. Osorio, A. Oszurek, O. Palacios, J. Hinsley, S. Pearce, C.L. Pike, M.C. Piskorz, A.M. Ray-Coquard, I. Rhenius, V. Rodriguez-Antona, C. Sharma, R. Sherman, M.E. De Silva, D. Singh, N. Sinn, P. Slamon, D. Song, H. Steed, H. Stronach, E.A. Thompson, P.J. Tołoczko, A. Trabert, B. Traficante, N. Tseng, C.-. Widschwendter, M. Wilkens, L.R. Winham, S.J. Winterhoff, B. Beeghly-Fadiel, A. Benitez, J. Berchuck, A. Brenton, J.D. Brown, R. Chang-Claude, J. Chenevix-Trench, G. deFazio, A. Fasching, P.A. García, M.J. Gayther, S.A. Goodman, M.T. Gronwald, J. Henderson, M.J. Karlan, B.Y. Kelemen, L.E. Menon, U. Orsulic, S. Pharoah, P.D. Wentzensen, N. Wu, A.H. Schildkraut, J.M. Rossing, M.A. Konecny, G.E. Huntsman, D.G. Huang, R.Y. Goode, E.L. Ramus, S.J. Doherty, J.A. Bowtell, D.D. Anglesio, M.S. (2020). Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical cancer research, Vol.26 (20), pp. 5411-5423.

Oza, A.M. Lorusso, D. Aghajanian, C. Oaknin, A. Dean, A. Colombo, N. Weberpals, J.I. Clamp, A.R. Scambia, G. Leary, A. Holloway, R.W. Gancedo, M.A. Fong, P.C. Goh, J.C. O’Malley, D.M. Armstrong, D.K. Banerjee, S. García-Donas, J. Swisher, E.M. Cella, D. Meunier, J. Goble, S. Cameron, T. Maloney, L. Mörk, A.-. Bedel, J. Ledermann, J.A. Coleman, R.L. (2020). Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. Journal of clinical oncology, Vol.38 (30), pp. 3494-3505.  show abstract

Tew, W.P. Lacchetti, C. Ellis, A. Maxian, K. Banerjee, S. Bookman, M. Jones, M.B. Lee, J.-. Lheureux, S. Liu, J.F. Moore, K.N. Muller, C. Rodriguez, P. Walsh, C. Westin, S.N. Kohn, E.C. (2020). PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. Journal of clinical oncology, Vol.38 (30), pp. 3468-3493.  show abstract

DiSilvestro, P. Colombo, N. Scambia, G. Kim, B.-. Oaknin, A. Friedlander, M. Lisyanskaya, A. Floquet, A. Leary, A. Sonke, G.S. Gourley, C. Banerjee, S. Oza, A. González-Martín, A. Aghajanian, C.A. Bradley, W.H. Mathews, C.A. Liu, J. Lowe, E.S. Bloomfield, R. Moore, K.N. (2020). Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. Journal of clinical oncology, Vol.38 (30), pp. 3528-3537.  show abstract

Lorusso, D. Ray-Coquard, I. Oaknin, A. Banerjee, S. (2020). Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change?. Esmo open, Vol.5 (5), pp. e000924-e000924.

Banerjee, S. Gonzalez-Martin, A. Harter, P. Lorusso, D. Moore, K.N. Oaknin, A. Ray-Coquard, I. (2020). First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion. Esmo open, Vol.5 (6), pp. e001110-e001110.

Chazan, G. Franchini, F. Alexander, M. Banerjee, S. Mileshkin, L. Blinman, P. Zielinski, R. Karikios, D. Pavlakis, N. Peters, S. Lordick, F. Ball, D. Wright, G. I. Jzerman, M. Solomon, B. (2020). Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. Esmo open, Vol.5 (6), pp. e001090-e001090.

Berner, A.M. Hughes, D.J. Tharmalingam, H. Baker, T. Heyworth, B. Banerjee, S. Saunders, D. (2020). An evaluation of self-perceived knowledge, attitudes and behaviours of UK oncologists about LGBTQ+ patients with cancer. Esmo open, Vol.5 (6), pp. e000906-e000906.

Murali, K. Banerjee, S. (2019). Let’s address burnout in oncologists and reimagine the way we work. Nature reviews clinical oncology, Vol.16 (1), pp. 1-2.

Castellani, F. Nganga, E.C. Dumas, L. Banerjee, S. Rockall, A.G. (2019). Imaging in the pre-operative staging of ovarian cancer. Abdominal radiology, Vol.44 (2), pp. 685-696.

Liposits, G. Loh, K.P. Soto-Perez-de-Celis, E. Dumas, L. Battisti, N.M. Kadambi, S. Baldini, C. Banerjee, S. Lichtman, S.M. (2019). PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. Journal of geriatric oncology, Vol.10 (2), pp. 337-345.

Colombo, N. Sessa, C. du Bois, A. Ledermann, J. McCluggage, W.G. McNeish, I. Morice, P. Pignata, S. Ray-Coquard, I. Vergote, I. Baert, T. Belaroussi, I. Dashora, A. Olbrecht, S. Planchamp, F. Querleu, D. Baert, T. Banerjee, S. Belaroussi, I. Blecharz, P. Bruchim, I. Cibula, D. Colombo, N. Concin, N. Davidson, B. Dashora, A. Devouassoux-Shisheboran, M. du Bois, A. Ferrero, A. Glasspool, R. González-Martin, A. Heinzelmann-Schwarz, V. Joly, F. Kim, J.W. Kridelka, F. Ledermann, J. Lorusso, D. Mahner, S. McCluggage, W.G. McNeish, I. Mikami, M. Mirza, M.R. Morice, P. Nicum, S. Olbrecht, S. O’Donnell, D.M. Pautier, P. Planchamp, F. Pignata, S. Querleu, D. Ray-Coquard, I. Rodolakis, A. Sehouli, J. Selcukbiricik, F. Sessa, C. Singh, N. Tan, D.S. Timmerman, D. Tognon, G. van der Velden, J. Vergote, I. Witteveen, P.O. Zeimet, A.G. (2019). ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of oncology, Vol.30 (5), pp. 672-705.

Colombo, N. Sessa, C. Bois, A.D. Ledermann, J. McCluggage, W.G. McNeish, I. Morice, P. Pignata, S. Ray-Coquard, I. Vergote, I. Baert, T. Belaroussi, I. Dashora, A. Olbrecht, S. Planchamp, F. Querleu, D. (2019). ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. International journal of gynecologic cancer, Vol.29 (4), pp. 728-760.  show abstract

Nawaz, S. Trahearn, N.A. Heindl, A. Banerjee, S. Maley, C.C. Sottoriva, A. Yuan, Y. (2019). Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer. Ebiomedicine, Vol.48, pp. 224-235.

Oza, A. Kaye, S. Van Tornout, J. Sessa, C. Gore, M. Naumann, R.W. Hirte, H. Colombo, N. Chen, J. Gorla, S. Poondru, S. Singh, M. Steinberg, J. Yuen, G. Banerjee, S. (2018). Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. Gynecologic oncology, Vol.149 (2), pp. 275-282.

Khalique, S. Naidoo, K. Attygalle, A.D. Kriplani, D. Daley, F. Lowe, A. Campbell, J. Jones, T. Hubank, M. Fenwick, K. Matthews, N. Rust, A.G. Lord, C.J. Banerjee, S. Natrajan, R. (2018). Optimised ARID1A immunohistochemistry is an accurate predictor ofARID1Amutational status in gynaecological cancers. The journal of pathology: clinical research, Vol.4 (3), pp. 154-166.

Heindl, A. Khan, A.M. Rodrigues, D.N. Eason, K. Sadanandam, A. Orbegoso, C. Punta, M. Sottoriva, A. Lise, S. Banerjee, S. Yuan, Y. (2018). Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity. Nature communications, Vol.9 (1).

Basu, B. Krebs, M.G. Sundar, R. Wilson, R.H. Spicer, J. Jones, R. Brada, M. Talbot, D.C. Steele, N. Ingles Garces, A.H. Brugger, W. Harrington, E.A. Evans, J. Hall, E. Tovey, H. de Oliveira, F.M. Carreira, S. Swales, K. Ruddle, R. Raynaud, F.I. Purchase, B. Dawes, J.C. Parmar, M. Turner, A.J. Tunariu, N. Banerjee, S. de Bono, J.S. Banerji, U. (2018). Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer. Ann oncol, .  show abstract

Khalique, S. Banerjee, S. (2017). Nintedanib in ovarian cancer. Expert opinion on investigational drugs, Vol.26 (9), pp. 1073-1081.

McLachlan, J. Boussios, S. Okines, A. Glaessgen, D. Bodlar, S. Kalaitzaki, R. Taylor, A. Lalondrelle, S. Gore, M. Kaye, S. Banerjee, S. (2017). The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. Clinical oncology, Vol.29 (3), pp. 153-160.

George, A. Banerjee, S. Kaye, S. (2017). Olaparib and somatic BRCA mutations. Oncotarget, Vol.8 (27), pp. 43598-43599.

George, A. Kaye, S. Banerjee, S. (2017). Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nature reviews clinical oncology, Vol.14 (5), pp. 284-296.

George, A. Kristeleit, R. Rafii, S. Michie, C.O. Bowen, R. Michalarea, V. van Hagen, T. Wong, M. Rallis, G. Molife, L.R. Lopez, J. Banerji, U. Banerjee, S.N. Gore, M.E. de Bono, J.S. Kaye, S.B. Yap, T.A. (2017). Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. European journal of cancer, Vol.76, pp. 52-59.

Capoluongo, E. Ellison, G. López-Guerrero, J.A. Penault-Llorca, F. Ligtenberg, M.J. Banerjee, S. Singer, C. Friedman, E. Markiefka, B. Schirmacher, P. Büttner, R. van Asperen, C.J. Ray-Coquard, I. Endris, V. Kamel-Reid, S. Percival, N. Bryce, J. Röthlisberger, B. Soong, R. de Castro, D.G. (2017). Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in oncology, Vol.44 (3), pp. 187-197.

Banerjee, S. Califano, R. Corral, J. de Azambuja, E. De Mattos-Arruda, L. Guarneri, V. Hutka, M. Jordan, K. Martinelli, E. Mountzios, G. Ozturk, M.A. Petrova, M. Postel-Vinay, S. Preusser, M. Qvortrup, C. Volkov, M.N. Tabernero, J. Olmos, D. Strijbos, M.H. (2017). Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. Annals of oncology, Vol.28 (7), pp. 1590-1596.

Pujade-Lauraine, E. Ledermann, J.A. Selle, F. Gebski, V. Penson, R.T. Oza, A.M. Korach, J. Huzarski, T. Poveda, A. Pignata, S. Friedlander, M. Colombo, N. Harter, P. Fujiwara, K. Ray-Coquard, I. Banerjee, S. Liu, J. Lowe, E.S. Bloomfield, R. Pautier, P. Korach, J. Huzarski, T. Byrski, T. Pautier, P. Friedlander, M. Harter, P. Colombo, N. Pignata, S. Scambia, G. Nicoletto, M. Nussey, F. Clamp, A. Penson, R. Oza, A. Poveda Velasco, A. Rodrigues, M. Lotz, J.-. Selle, F. Ray-Coquard, I. Provencher, D. Prat Aparicio, A. Vidal Boixader, L. Scott, C. Tamura, K. Yunokawa, M. Lisyanskaya, A. Medioni, J. Pécuchet, N. Dubot, C. de la Motte Rouge, T. Kaminsky, M.-. Weber, B. Lortholary, A. Parkinson, C. Ledermann, J. Williams, S. Banerjee, S. Cosin, J. Hoffman, J. Penson, R. Plante, M. Covens, A. Sonke, G. Joly, F. Floquet, A. Banerjee, S. Hirte, H. Amit, A. Park-Simon, T.-. Matsumoto, K. Tjulandin, S. Kim, J.H. Gladieff, L. Sabbatini, R. O'Malley, D. Timmins, P. Kredentser, D. Laínez Milagro, N. Barretina Ginesta, M.P. Tibau Martorell, A. Gómez de Liaño Lista, A. Ojeda González, B. Mileshkin, L. Mandai, M. Boere, I. Ottevanger, P. Nam, J.-. Filho, E. Hamizi, S. Cognetti, F. Warshal, D. Dickson-Michelson, E. Kamelle, S. McKenzie, N. Rodriguez, G. Armstrong, D. Chalas, E. Celano, P. Behbakht, K. Davidson, S. Welch, S. Helpman, L. Fishman, A. Bruchim, I. Sikorska, M. Słowińska, A. Rogowski, W. Bidziński, M. Śpiewankiewicz, B. Casado Herraez, A. Mendiola Fernández, C. Gropp-Meier, M. Saito, T. Takehara, K. Enomoto, T. Watari, H. Choi, C.H. Kim, B.-. Kim, J.W. Hegg, R. Vergote, I. (2017). Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The lancet oncology, Vol.18 (9), pp. 1274-1284.

Banerjee, S. Preusser, M. Tabernero, J. Strijbos, M. (2017). Reply to the letter to the editor ‘Can we trust burnout research?’ by Bianchi et al. Annals of oncology, Vol.28 (10), pp. 2625-2626.

Banerjee, S. (2017). Bevacizumab in cervical cancer: a step forward for survival. The lancet, Vol.390 (10103), pp. 1626-1628.

George, A. McLachlan, J. Tunariu, N. Della Pepa, C. Migali, C. Gore, M. Kaye, S. Banerjee, S. (2017). The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. Bmc cancer, Vol.17 (1).

Orbegoso, C. Marquina, G. George, A. Banerjee, S. (2017). The role of Cediranib in ovarian cancer. Expert opinion on pharmacotherapy, Vol.18 (15), pp. 1637-1648.

Rafii, S. Gourley, C. Kumar, R. Geuna, E. Ang, J.E. Rye, T. Chen, L.-. Shapira-Frommer, R. Friedlander, M. Matulonis, U. Greve, J.D. Oza, A.M. Banerjee, S. Rhoda Molife, L. Gore, M.E. Kaye, S.B. Yap, T.A. (2017). Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget, Vol.8 (29), pp. 47154-47160.

Dolly, S.O. Migali, C. Tunariu, N. Della-Pepa, C. Khakoo, S. Hazell, S. de Bono, J.S. Kaye, S.B. Banerjee, S. (2017). Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. Esmo open, Vol.2 (1), pp. e000101-e000101.

Phelan, C.M. Kuchenbaecker, K.B. Tyrer, J.P. Kar, S.P. Lawrenson, K. Winham, S.J. Dennis, J. Pirie, A. Riggan, M.J. Chornokur, G. Earp, M.A. Lyra, P.C. Lee, J.M. Coetzee, S. Beesley, J. McGuffog, L. Soucy, P. Dicks, E. Lee, A. Barrowdale, D. Lecarpentier, J. Leslie, G. Aalfs, C.M. Aben, K.K. Adams, M. Adlard, J. Andrulis, I.L. Anton-Culver, H. Antonenkova, N. group, A.S. Aravantinos, G. Arnold, N. Arun, B.K. Arver, B. Azzollini, J. Balmana, J. Banerjee, S.N. Barjhoux, L. Barkardottir, R.B. Bean, Y. Beckmann, M.W. Beeghly-Fadiel, A. Benitez, J. Bermisheva, M. Bernardini, M.Q. Birrer, M.J. Bjorge, L. Black, A. Blankstein, K. Blok, M.J. Bodelon, C. Bogdanova, N. Bojesen, A. Bonanni, B. Borg, A. Bradbury, A.R. Brenton, J.D. Brewer, C. Brinton, L. Broberg, P. Brooks-Wilson, A. Bruinsma, F. Brunet, J. Buecher, B. Butzow, R. Buys, S.S. Caldes, T. Caligo, M.A. Campbell, I. Cannioto, R. Carney, M.E. Cescon, T. Chan, S.B. Chang-Claude, J. Chanock, S. Chen, X.Q. Chiew, Y.E. Chiquette, J. Chung, W.K. Claes, K.B. Conner, T. Cook, L.S. Cook, J. Cramer, D.W. Cunningham, J.M. D'Aloisio, A.A. Daly, M.B. Damiola, F. Damirovna, S.D. Dansonka-Mieszkowska, A. Dao, F. Davidson, R. DeFazio, A. Delnatte, C. Doheny, K.F. Diez, O. Ding, Y.C. Doherty, J.A. Domchek, S.M. Dorfling, C.M. Dork, T. Dossus, L. Duran, M. Durst, M. Dworniczak, B. Eccles, D. Edwards, T. Eeles, R. Eilber, U. Ejlertsen, B. Ekici, A.B. Ellis, S. Elvira, M. Study, E. Eng, K.H. Engel, C. Evans, D.G. Fasching, P.A. Ferguson, S. Ferrer, S.F. Flanagan, J.M. Fogarty, Z.C. Fortner, R.T. Fostira, F. Foulkes, W.D. Fountzilas, G. Fridley, B.L. Friebel, T.M. Friedman, E. Frost, D. Ganz, P.A. Garber, J. Garcia, M.J. Garcia-Barberan, V. Gehrig, A. Collaborators, G.S. Gentry-Maharaj, A. Gerdes, A.M. Giles, G.G. Glasspool, R. Glendon, G. Godwin, A.K. Goldgar, D.E. Goranova, T. Gore, M. Greene, M.H. Gronwald, J. Gruber, S. Hahnen, E. Haiman, C.A. Hakansson, N. Hamann, U. Hansen, T.V. Harrington, P.A. Harris, H.R. Hauke, J. Study, H. Hein, A. Henderson, A. Hildebrandt, M.A. Hillemanns, P. Hodgson, S. Hogdall, C.K. Hogdall, E. Hogervorst, F.B. Holland, H. Hooning, M.J. Hosking, K. Huang, R.Y. Hulick, P.J. Hung, J. Hunter, D.J. Huntsman, D.G. Huzarski, T. Imyanitov, E.N. Isaacs, C. Iversen, E.S. Izatt, L. Izquierdo, A. Jakubowska, A. James, P. Janavicius, R. Jernetz, M. Jensen, A. Jensen, U.B. John, E.M. Johnatty, S. Jones, M.E. Kannisto, P. Karlan, B.Y. Karnezis, A. Kast, K. Investigators, K.C. Kennedy, C.J. Khusnutdinova, E. Kiemeney, L.A. Kiiski, J.I. Kim, S.W. Kjaer, S.K. Kobel, M. Kopperud, R.K. Kruse, T.A. Kupryjanczyk, J. Kwong, A. Laitman, Y. Lambrechts, D. Larranaga, N. Larson, M.C. Lazaro, C. Le, N.D. Le Marchand, L. Lee, J.W. Lele, S.B. Leminen, A. Leroux, D. Lester, J. Lesueur, F. Levine, D.A. Liang, D. Liebrich, C. Lilyquist, J. Lipworth, L. Lissowska, J. Lu, K.H. Lubinnski, J. Luccarini, C. Lundvall, L. Mai, P.L. Mendoza-Fandino, G. Manoukian, S. Massuger, L. May, T. Mazoyer, S. McAlpine, J.N. McGuire, V. McLaughlin, J.R. McNeish, I. Meijers-Heijboer, H. Meindl, A. Menon, U. Mensenkamp, A.R. Merritt, M.A. Milne, R.L. Mitchell, G. Modugno, F. Moes-Sosnowska, J. Moffitt, M. Montagna, M. Moysich, K.B. Mulligan, A.M. Musinsky, J. Nathanson, K.L. Nedergaard, L. Ness, R.B. Neuhausen, S.L. Nevanlinna, H. Niederacher, D. Nussbaum, R.L. Odunsi, K. Olah, E. Olopade, O.I. Olsson, H. Olswold, C. O'Malley, D.M. Ong, K.R. Onland-Moret, N.C. group, O.S. Orr, N. Orsulic, S. Osorio, A. Palli, D. Papi, L. Park-Simon, T.W. Paul, J. Pearce, C.L. Pedersen, I.S. Peeters, P.H. Peissel, B. Peixoto, A. Pejovic, T. Pelttari, L.M. Permuth, J.B. Peterlongo, P. Pezzani, L. Pfeiler, G. Phillips, K.A. Piedmonte, M. Pike, M.C. Piskorz, A.M. Poblete, S.R. Pocza, T. Poole, E.M. Poppe, B. Porteous, M.E. Prieur, F. Prokofyeva, D. Pugh, E. Pujana, M.A. Pujol, P. Radice, P. Rantala, J. Rappaport-Fuerhauser, C. Rennert, G. Rhiem, K. Rice, P. Richardson, A. Robson, M. Rodriguez, G.C. Rodriguez-Antona, C. Romm, J. Rookus, M.A. Rossing, M.A. Rothstein, J.H. Rudolph, A. Runnebaum, I.B. Salvesen, H.B. Sandler, D.P. Schoemaker, M.J. Senter, L. Setiawan, V.W. Severi, G. Sharma, P. Shelford, T. Siddiqui, N. Side, L.E. Sieh, W. Singer, C.F. Sobol, H. Song, H. Southey, M.C. Spurdle, A.B. Stadler, Z. Steinemann, D. Stoppa-Lyonnet, D. Sucheston-Campbell, L.E. Sukiennicki, G. Sutphen, R. Sutter, C. Swerdlow, A.J. Szabo, C.I. Szafron, L. Tan, Y.Y. Taylor, J.A. Tea, M.K. Teixeira, M.R. Teo, S.H. Terry, K.L. Thompson, P.J. Thomsen, L.C. Thull, D.L. Tihomirova, L. Tinker, A.V. Tischkowitz, M. Tognazzo, S. Toland, A.E. Tone, A. Trabert, B. Travis, R.C. Trichopoulou, A. Tung, N. Tworoger, S.S. van Altena, A.M. Van Den Berg, D. van der Hout, A.H. van der Luijt, R.B. Van Heetvelde, M. Van Nieuwenhuysen, E. van Rensburg, E.J. Vanderstichele, A. Varon-Mateeva, R. Vega, A. Edwards, D.V. Vergote, I. Vierkant, R.A. Vijai, J. Vratimos, A. Walker, L. Walsh, C. Wand, D. Wang-Gohrke, S. Wappenschmidt, B. Webb, P.M. Weinberg, C.R. Weitzel, J.N. Wentzensen, N. Whittemore, A.S. Wijnen, J.T. Wilkens, L.R. Wolk, A. Woo, M. Wu, X. Wu, A.H. Yang, H. Yannoukakos, D. Ziogas, A. Zorn, K.K. Narod, S.A. Easton, D.F. Amos, C.I. Schildkraut, J.M. Ramus, S.J. Ottini, L. Goodman, M.T. Park, S.K. Kelemen, L.E. Risch, H.A. Thomassen, M. Offit, K. Simard, J. Schmutzler, R.K. Hazelett, D. Monteiro, A.N. Couch, F.J. Berchuck, A. Chenevix-Trench, G. Goode, E.L. Sellers, T.A. Gayther, S.A. Antoniou, A.C. Pharoah, P.D. (2017). Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat genet, Vol.49, pp. 680-691.  show abstract

Heath, O.M. van Beekhuizen, H.J. Nama, V. Kolomainen, D. Nobbenhuis, M.A. Ind, T.E. Sohaib, S.A. Lofts, F.J. Heenan, S. Gore, M. Banerjee, S. Kaye, S.B. Barton, D.P. (2016). Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases. Thrombosis research, Vol.137, pp. 30-35.

McLachlan, J. Banerjee, S. (2016). Olaparib for the treatment of epithelial ovarian cancer. Expert opinion on pharmacotherapy, Vol.17 (7), pp. 995-1003.

McLachlan, J. Lima, J.P. Dumas, L. Banerjee, S. (2016). Targeted agents and combinations in ovarian cancer: where are we now?. Expert review of anticancer therapy, Vol.16 (4), pp. 441-454.

Moschetta, M. George, A. Kaye, S.B. Banerjee, S. (2016). BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Annals of oncology, Vol.27 (8), pp. 1449-1455.

Dumas, L. Ring, A. Butler, J. Kalsi, T. Harari, D. Banerjee, S. (2016). Improving outcomes for older women with gynaecological malignancies. Cancer treatment reviews, Vol.50, pp. 99-108.

Friedlander, M. Banerjee, S. Mileshkin, L. Scott, C. Shannon, C. Goh, J. (2016). Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum‐sensitive recurrent ovarian cancer. Asia-pacific journal of clinical oncology, Vol.12 (4), pp. 323-331.

Vergote, I. Banerjee, S. Gerdes, A.-. van Asperen, C. Marth, C. Vaz, F. Ray-Coquard, I. Stoppa-Lyonnet, D. Gonzalez-Martin, A. Sehouli, J. Colombo, N. (2016). Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. European journal of cancer, Vol.69, pp. 127-134.

Percival, N. George, A. Gyertson, J. Hamill, M. Fernandes, A. Davies, E. Rahman, N. Banerjee, S. (2016). The integration of BRCA testing into oncology clinics. British journal of nursing, Vol.25 (12), pp. 690-694.

Meeks, H.D. Song, H. Michailidou, K. Bolla, M.K. Dennis, J. Wang, Q. Barrowdale, D. Frost, D. Embrace, McGuffog, L. Ellis, S. Feng, B. Buys, S.S. Hopper, J.L. Southey, M.C. Tesoriero, A. kConFab, I. James, P.A. Bruinsma, F. Campbell, I.G. Australia Ovarian Cancer Study, G. Broeks, A. Schmidt, M.K. Hogervorst, F.B. Hebon, Beckman, M.W. Fasching, P.A. Fletcher, O. Johnson, N. Sawyer, E.J. Riboli, E. Banerjee, S. Menon, U. Tomlinson, I. Burwinkel, B. Hamann, U. Marme, F. Rudolph, A. Janavicius, R. Tihomirova, L. Tung, N. Garber, J. Cramer, D. Terry, K.L. Poole, E.M. Tworoger, S.S. Dorfling, C.M. van Rensburg, E.J. Godwin, A.K. Guenel, P. Truong, T. Collaborators, G.S. Stoppa-Lyonnet, D. Damiola, F. Mazoyer, S. Sinilnikova, O.M. Isaacs, C. Maugard, C. Bojesen, S.E. Flyger, H. Gerdes, A.M. Hansen, T.V. Jensen, A. Kjaer, S.K. Hogdall, C. Hogdall, E. Pedersen, I.S. Thomassen, M. Benitez, J. Gonzalez-Neira, A. Osorio, A. Hoya Mde, L. Segura, P.P. Diez, O. Lazaro, C. Brunet, J. Anton-Culver, H. Eunjung, L. John, E.M. Neuhausen, S.L. Ding, Y.C. Castillo, D. Weitzel, J.N. Ganz, P.A. Nussbaum, R.L. Chan, S.B. Karlan, B.Y. Lester, J. Wu, A. Gayther, S. Ramus, S.J. Sieh, W. Whittermore, A.S. Monteiro, A.N. Phelan, C.M. Terry, M.B. Piedmonte, M. Offit, K. Robson, M. Levine, D. Moysich, K.B. Cannioto, R. Olson, S.H. Daly, M.B. Nathanson, K.L. Domchek, S.M. Lu, K.H. Liang, D. Hildebrant, M.A. Ness, R. Modugno, F. Pearce, L. Goodman, M.T. Thompson, P.J. Brenner, H. Butterbach, K. Meindl, A. Hahnen, E. Wappenschmidt, B. Brauch, H. Bruning, T. Blomqvist, C. Khan, S. Nevanlinna, H. Pelttari, L.M. Aittomaki, K. Butzow, R. Bogdanova, N.V. Dork, T. Lindblom, A. Margolin, S. Rantala, J. Kosma, V.M. Mannermaa, A. Lambrechts, D. Neven, P. Claes, K.B. Maerken, T.V. Chang-Claude, J. Flesch-Janys, D. Heitz, F. Varon-Mateeva, R. Peterlongo, P. Radice, P. Viel, A. Barile, M. Peissel, B. Manoukian, S. Montagna, M. Oliani, C. Peixoto, A. Teixeira, M.R. Collavoli, A. Hallberg, E. Olson, J.E. Goode, E.L. Hart, S.N. Shimelis, H. Cunningham, J.M. Giles, G.G. Milne, R.L. Healey, S. Tucker, K. Haiman, C.A. Henderson, B.E. Goldberg, M.S. Tischkowitz, M. Simard, J. Soucy, P. Eccles, D.M. Le, N. Borresen-Dale, A.L. Kristensen, V. Salvesen, H.B. Bjorge, L. Bandera, E.V. Risch, H. Zheng, W. Beeghly-Fadiel, A. Cai, H. Pylkas, K. Tollenaar, R.A. Ouweland, A.M. Andrulis, I.L. Knight, J.A. Ocgn, Narod, S. Devilee, P. Winqvist, R. Figueroa, J. Greene, M.H. Mai, P.L. Loud, J.T. Garcia-Closas, M. Schoemaker, M.J. Czene, K. Darabi, H. McNeish, I. Siddiquil, N. Glasspool, R. Kwong, A. Park, S.K. Teo, S.H. Yoon, S.Y. Matsuo, K. Hosono, S. Woo, Y.L. Gao, Y.T. Foretova, L. Singer, C.F. Rappaport-Feurhauser, C. Friedman, E. Laitman, Y. Rennert, G. Imyanitov, E.N. Hulick, P.J. Olopade, O.I. Senter, L. Olah, E. Doherty, J.A. Schildkraut, J. Koppert, L.B. Kiemeney, L.A. Massuger, L.F. Cook, L.S. Pejovic, T. Li, J. Borg, A. Ofverholm, A. Rossing, M.A. Wentzensen, N. Henriksson, K. Cox, A. Cross, S.S. Pasini, B.J. Shah, M. Kabisch, M. Torres, D. Jakubowska, A. Lubinski, J. Gronwald, J. Agnarsson, B.A. Kupryjanczyk, J. Moes-Sosnowska, J. Fostira, F. Konstantopoulou, I. Slager, S. Jones, M. genome, P.R. Antoniou, A.C. Berchuck, A. Swerdlow, A. Chenevix-Trench, G. Dunning, A.M. Pharoah, P.D. Hall, P. Easton, D.F. Couch, F.J. Spurdle, A.B. Goldgar, D.E. (2016). BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J natl cancer inst, Vol.108.  show abstract

Morgan, G. Lambertini, M. Kourie, H.R. Amaral, T. Argiles, G. Banerjee, S. Cardone, C. Corral, J. De Mattos-Arruda, L. öztürk, A. Petrova, M. Poulsen, L. Strijbos, M. Tyulyandina, A. Vidra, R. Califano, R. de Azambuja, E. Garrido Lopez, P. Guarneri, V. Reck, M. Moiseyenko, V. Martinelli, E. Douillard, J.-. Stahel, R. Voest, E. Arnold, D. Cardoso, F. Casali, P. Cervantes, A. Eggermont, A.M. Eniu, A. Jassem, J. Pentheroudakis, G. Peters, S. McGregor, K. Rauh, S. Zielinski, C.C. Ciardiello, F. Tabernero, J. Preusser, M. (2016). Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). Esmo open, Vol.1 (6), pp. e000107-e000107.

Dittrich, C. Kosty, M. Jezdic, S. Pyle, D. Berardi, R. Bergh, J. El-Saghir, N. Lotz, J.-. Österlund, P. Pavlidis, N. Purkalne, G. Awada, A. Banerjee, S. Bhatia, S. Bogaerts, J. Buckner, J. Cardoso, F. Casali, P. Chu, E. Close, J.L. Coiffier, B. Connolly, R. Coupland, S. De Petris, L. De Santis, M. de Vries, E.G. Dizon, D.S. Duff, J. Duska, L.R. Eniu, A. Ernstoff, M. Felip, E. Fey, M.F. Gilbert, J. Girard, N. Glaudemans, A.W. Gopalan, P.K. Grothey, A. Hahn, S.M. Hanna, D. Herold, C. Herrstedt, J. Homicsko, K. Jones, D.V. Jost, L. Keilholz, U. Khan, S. Kiss, A. Köhne, C.-. Kunstfeld, R. Lenz, H.E. Lichtman, S. Licitra, L. Lion, T. Litière, S. Liu, L. Loehrer, P.J. Markham, M.J. Markman, B. Mayerhoefer, M. Meran, J.G. Michielin, O. Moser, E.C. Mountzios, G. Moynihan, T. Nielsen, T. Ohe, Y. Öberg, K. Palumbo, A. Peccatori, F.A. Pfeilstöcker, M. Raut, C. Remick, S.C. Robson, M. Rutkowski, P. Salgado, R. Schapira, L. Schernhammer, E. Schlumberger, M. Schmoll, H.-. Schnipper, L. Sessa, C. Shapiro, C.L. Steele, J. Sternberg, C.N. Stiefel, F. Strasser, F. Stupp, R. Sullivan, R. Tabernero, J. Travado, L. Verheij, M. Voest, E. Vokes, E. Von Roenn, J. Weber, J.S. Wildiers, H. Yarden, Y. (2016). ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. Esmo open, Vol.1 (5), pp. e000097-e000097.

McLachlan, J. Banerjee, S. (2015). Pazopanib in ovarian cancer. Expert review of anticancer therapy, Vol.15 (9), pp. 995-1005.

Younger, E. Okines, A.F. Tan, D.S. Anandappa, G. Tokaca, N. Thomas, B. Gore, M. Kaye, S. Banerjee, S. (2015). CARBOPLATIN DESENSITISATION EXPERIENCE IN CLINICAL PRACTICE. International journal of gynecological cancer, Vol.25 (9), pp. 508-508.

Lima, J. Mclachlan, J. della Peppa, C. Nobbenhuis, M. Gore, M. Kaye, S. Banerjee, S. (2015). CLINICAL OUTCOMES OF LOW GRADE SEROUS OVARIAN CARCINOMA: A TWENTY FIVE YEAR RETROSPECTIVE CASE SERIES OF THE ROYAL MARSDEN EXPERIENCE. International journal of gynecological cancer, Vol.25 (9), pp. 1420-1421.

Kolomainen, D.F. Butler, J. Barton, D.P. Ind, T.E. Nobbenhuis, M.A. Lalondrelle, S. Taylor, A. Shepherd, J.H. Gore, M.E. Kaye, S.B. Banerjee, S. (2015). IS THERE A SURVIVAL BENEFIT FOR PATIENTS WHO RECEIVE POST-OPERATIVE ADJUVANT CHEMOTHERAPY FOLLOWING SECONDARY CYTOREDUCTIVE SURGERY (SCRS) FOR RECURRENT EPITHELIAL OVARIAN CANCER (EOC)?. International journal of gynecological cancer, Vol.25 (9), pp. 1407-1407.

Heath, O. van Beekhuizen, H. Kolomainen, D. Nama, V. Nobbenhuis, M. Ind, T. Sohaib, A. Lofts, F. Heenan, S. Gore, M. Banerjee, S. Kaye, S. Barton, D. (2015). SYMPTOMATIC AND ASYMPTOMATIC VENOUS THROMBOEMBOLISM AT TIME OF DIAGNOSIS OF PRIMARY OVARIAN CANCER. International journal of gynecological cancer, Vol.25 (9), pp. 387-387.

Seifert, H. Georgiou, A. Alexander, H. McLachlan, J. Bodla, S. Kaye, S. Barton, D. Nobbenhuis, M. Gore, M. Banerjee, S. (2015). Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC). Gynecologic oncology, Vol.139 (2), pp. 216-220.

Seifert, H. Georgiou, A. Alexander, H. McLachlan, J. Bodla, S. Kaye, S. Barton, D. Nobbenhuis, M. Gore, M. Banerjee, S. (2015). Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC). Gynecologic oncology, Vol.139 (2), pp. 216-220.

Symonds, R.P. Gourley, C. Davidson, S. Carty, K. McCartney, E. Rai, D. Banerjee, S. Jackson, D. Lord, R. McCormack, M. Hudson, E. Reed, N. Flubacher, M. Jankowska, P. Powell, M. Dive, C. West, C.M. Paul, J. (2015). Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. The lancet oncology, Vol.16 (15), pp. 1515-1524.

Lan, C. Heindl, A. Huang, X. Xi, S. Banerjee, S. Liu, J. Yuan, Y. (2015). Quantitative histology analysis of the ovarian tumour microenvironment. Scientific reports, Vol.5 (1).

Banerjee, S. Stanway, S. (2015). Problem solving in acute oncology. British journal of cancer, Vol.113 (12), pp. 1744-1745.

Boussios, S. Attygalle, A. Hazell, S. Moschetta, M. Mclachlan, J. Okines, A. Banerjee, S. (2015). Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review. Anticancer research, Vol.35 (12), pp. 6713-6722.

Boussios, S. Moschetta, M. McLachlan, J. Banerjee, S. (2015). Bleomycin-Induced Flagellate Erythema in a Patient Diagnosed with Ovarian Yolk Sac Tumor. Case reports in oncological medicine, Vol.2015, pp. 1-2.  show abstract

Syrios, J. Banerjee, S. Kaye, S.B. (2014). Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets - Where Are we Now?. Anticancer research, Vol.34 (5), pp. 2069-2077.

Califano, R. Karamouzis, M.V. Banerjee, S. de Azambuja, E. Guarneri, V. Hutka, M. Jordan, K. Kamposioras, K. Martinelli, E. Corral, J. Postel-Vinay, S. Preusser, M. Porcu, L. Torri, V. (2014). Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee. Lung cancer, Vol.85 (1), pp. 74-80.  show abstract

Nobbenhuis, M.A. Lalondrelle, S. Larkin, J. Banerjee, S. (2014). Management of melanomas of the gynaecological tract. Curr opin oncol, Vol.26 (5), pp. 508-513.  show abstract

Penson, R.T. Moore, K.M. Fleming, G.F. Braly, P. Schimp, V. Nguyen, H. Matulonis, U.A. Banerjee, S. Haluska, P. Gore, M. Bodurka, D.C. Hozak, R.R. Joshi, A. Xu, Y. Schwartz, J.D. McGuire, W.P. (2014). A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol oncol, Vol.134 (3), pp. 478-485.  show abstract

George, A. Smith, F. Cloke, V. Gore, M.E. Hanson, H. Banerjee, S. Rahman, N. (2014). Implementation of Routine Brca Gene Testing of Ovarian Cancer (Oc) Patients at Royal Marsden Hospital. Annals of oncology, Vol.25, pp. iv307-iv307.

Canario, R. Lima, J.P. Migali, C. Tunariu, N. George, A. Kaye, S.B. Gore, M.E. Banerjee, S. (2014). Clinical Outcomes of Recurrent Ovarian Granulosa Cell Tumours Treated with Letrozole: a 10-Year Retrospective Case-Series of the Royal Marsden Hospital. Annals of oncology, Vol.25, pp. iv305-iv305.

McNeish, I.A. Ledermann, J.A. Webber, L. James, L. Kaye, S.B. Hall, M. Hall, G. Clamp, A. Earl, H. Banerjee, S. Kristeleit, R. Raja, F. Feeney, A. Lawrence, C. Dawson-Athey, L. Persic, M. Khan, I. (2014). A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. Ann oncol, Vol.25 (10), pp. 1988-1995.  show abstract

Thway, K. Hazell, S. Banerjee, S. Fisher, C. (2014). Rhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma. Case rep pathol, Vol.2014, p. 238545.  show abstract

Della Pepa, C. Banerjee, S. (2014). Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. Onco targets ther, Vol.7, pp. 1025-1032.  show abstract

Weigel, M.T. Banerjee, S. Arnedos, M. Salter, J. A'Hern, R. Dowsett, M. Martin, L.A. (2013). Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Ann oncol, Vol.24 (1), pp. 126-133.  show abstract

Ang, J.E. Gourley, C. Powell, C.B. High, H. Shapira-Frommer, R. Castonguay, V. De Greve, J. Atkinson, T. Yap, T.A. Sandhu, S. Banerjee, S. Chen, L.-. Friedlander, M.L. Kaufman, B. Oza, A.M. Matulonis, U. Barber, L.J. Kozarewa, I. Fenwick, K. Assiotis, I. Campbell, J. Chen, L. de Bono, J.S. Gore, M.E. Lord, C.J. Ashworth, A. Kaye, S.B. (2013). Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin cancer res, Vol.19 (19), pp. 5485-5493.  show abstract

Banerjee, S. Kaye, S.B. (2013). New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin cancer res, Vol.19 (5), pp. 961-968.  show abstract

Banerjee, S. Rustin, G. Paul, J. Williams, C. Pledge, S. Gabra, H. Skailes, G. Lamont, A. Hindley, A. Goss, G. Gilby, E. Hogg, M. Harper, P. Kipps, E. Lewsley, L.-. Hall, M. Vasey, P. Kaye, S.B. (2013). A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann oncol, Vol.24 (3), pp. 679-687.  show abstract

Tan, D.S. Yap, T.A. Hutka, M. Roxburgh, P. Ang, J. Banerjee, S. Grzybowska, E. Gourley, C. Gore, M.E. Kaye, S.B. (2013). Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eur j cancer, Vol.49 (6), pp. 1246-1253.  show abstract

Banerjee, S. Gore, M. (2013). Personalized therapy in gynecological cancer: a reality in clinical practice?. Curr oncol rep, Vol.15 (3), pp. 201-203.

Miller, R.E. Banerjee, S. (2013). The current state of pemetrexed in ovarian cancer. Expert opin investig drugs, Vol.22 (9), pp. 1201-1210.  show abstract

Jenkins, V. Catt, S. Banerjee, S. Gourley, C. Montes, A. Solis-Trapala, I. Monson, K. Fallowfield, L. (2013). Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the UK: results from the ADVOCATE study. British journal of cancer, Vol.108 (11), pp. 2264-2271.

Lopez, J. Banerjee, S. Kaye, S.B. (2013). New developments in the treatment of ovarian cancer--future perspectives. Ann oncol, Vol.24 Suppl 10, pp. x69-x76.  show abstract

Weigelt, B. Banerjee, S. (2012). Molecular targets and targeted therapeutics in endometrial cancer. Current opinion in oncology, Vol.24 (5), pp. 554-563.

Banerjee, S. Kaye, S. (2012). Progression-free survival versus overall survival in ovarian cancer: where are we now?. Curr oncol rep, Vol.14 (6), pp. 483-485.

Banerjee, S. Gore, M. (2012). Recent advances in systemic treatments for ovarian cancer. Cancer imaging, Vol.12, pp. 305-309.  show abstract

Banerjee, S. Kaye, S.B. (2012). Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?. Nat rev clin oncol, Vol.9 (4), pp. 194-196.

Banerjee, S. (2011). The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. Steroids, Vol.76 (8), pp. 807-811.  show abstract

Banerjee, S. Kaye, S. (2011). The role of targeted therapy in ovarian cancer. Eur j cancer, Vol.47 Suppl 3, pp. S116-S130.  show abstract

Sanfilippo, R. Grosso, F. Jones, R.L. Banerjee, S. Pilotti, S. D'Incalci, M. Tos, A.P. Raspagliesi, F. Judson, I. Casali, P.G. (2011). Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. Gynecologic oncology, Vol.123 (3), pp. 553-556.

Banerjee, S. Kaye, S. (2011). PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr oncol rep, Vol.13 (6), pp. 442-449.  show abstract

Weigel, M.T. Banerjee, S. A'Hern, R. Arnedos, M. Ghazoui, Z. Dunbier, A.K. Dowsett, M. Martin, L.-. (2011). P4-01-01: Preclinical and Clinical Studies of Estrogen Deprivation Support the PDGF/Abl Pathway as a Novel Therapeutic Target for Overcoming Resistance. Poster session abstracts, .

Banerjee, S.N. Mitchell, S. Al-Muderis, O. Pennert, K. Dunlop, A. Propert-Lewis, C. Judson, I.R. Scurr, M.R. (2011). The Royal Marsden Hospital experience of trabectedin in patients with advanced soft tissue sarcoma (STS): Toxicity and efficacy in a nonselected group. Journal of clinical oncology, Vol.29 (15).

Banerjee, S.N. Mitchell, S. Al-Muderis, O. Pennert, K. Dunlop, A. Propert-Lewis, C. Judson, I.R. Scurr, M.R. (2011). The Royal Marsden Hospital experience of trabectedin in patients with advanced soft tissue sarcoma (STS): Toxicity and efficacy in a nonselected group. J clin oncol, Vol.29 (15_suppl), p. e20507.  show abstract

Harb, W.A. Sessa, C. Hirte, H.W. Kaye, S.B. Simantov, R. Banerjee, S.N. Christinat, A. Sternberg, D.W. Singh, M. Light, R. Poondru, S. (2011). A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors. Journal of clinical oncology, Vol.29 (15).

Banerjee, S. Kaye, S.B. Ashworth, A. (2010). Making the best of PARP inhibitors in ovarian cancer. Nature reviews clinical oncology, Vol.7 (9), pp. 508-12.

Banerjee, S. (2010). Becoming a new consultant: how to make it work for you. Clin med (lond), Vol.10 (1), pp. 41-42.

Banerjee, S. Cunningham, D. (2010). Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions. Clin colorectal cancer, Vol.9 Suppl 1, pp. S28-S35.  show abstract

Banerjee, S. Smith, I.E. (2010). Management of small HER2-positive breast cancers. Lancet oncol, Vol.11 (12), pp. 1193-1199.  show abstract

Banerjee, S. A'Hern, R. Detre, S. Littlewood-Evans, A.J. Evans, D.B. Dowsett, M. Martin, L.-. (2010). Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo. Clinical cancer research, Vol.16 (16), pp. 4178-10.

Banerjee, S. A'Hern, R. Detre, S. Littlewood-Evans, A.J. Evans, D.B. Dowsett, M. Martin, L.-. (2010). Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. Clin cancer res, Vol.16 (16), pp. 4178-4187.  show abstract

Banerjee, S. Zvelebil, M. Furet, P. Mueller-Vieira, U. Evans, D.B. Dowsett, M. Martin, L.-. (2009). The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase. Cancer res, Vol.69 (11), pp. 4716-4723.  show abstract

Banerjee, S. Gore, M. (2009). The future of targeted therapies in ovarian cancer. Oncologist, Vol.14 (7), pp. 706-716.  show abstract

Smith, I.E. Banerjee, S. (2009). The follow-up of women at high risk for breast cancer relapse. Breast, Vol.18 Suppl 3, pp. S74-S77.

Banerjee, S. Pancholi, S. A'hern, R. Ghazoui, Z. Smith, I.E. Dowsett, M. Martin, L.-. (2008). The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer. Clin cancer res, Vol.14 (9), pp. 2656-2663.  show abstract

Pancholi, S. Lykkesfeldt, A.E. Hilmi, C. Banerjee, S. Leary, A. Drury, S. Johnston, S. Dowsett, M. Martin, L.-. (2008). ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr relat cancer, Vol.15 (4), pp. 985-1002.  show abstract

Banerjee, S. Dowsett, M. Ashworth, A. Martin, L.-. (2007). Mechanisms of disease: angiogenesis and the management of breast cancer. Nat clin pract oncol, Vol.4 (9), pp. 536-550.  show abstract

Banerjee, S. Reis-Filho, J.S. Ashley, S. Steele, D. Ashworth, A. Lakhani, S.R. Smith, I.E. (2006). Basal-like breast carcinomas: clinical outcome and response to chemotherapy. Journal of clinical pathology, Vol.59 (7), pp. 729-7.

Banerjee, S. Reis-Filho, J.S. Ashley, S. Steele, D. Ashworth, A. Lakhani, S.R. Smith, I.E. (2006). Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J clin pathol, Vol.59 (7), pp. 729-735.  show abstract

Lee, J.C. Banerjee, S. King, D.M. (2005). Breast or chest? A diagnostic conundrum. British journal of radiology, Vol.78 (929), pp. 471-472.

Banerjee, S. Smith, I.E. Folkerd, L. Iqbal, J. Barker, P. Dowsett, M. IMPACT trialists, (2005). Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann oncol, Vol.16 (10), pp. 1632-1638.  show abstract

Parton, M. Maisey, N. Banerjee, S. Harper-Wynne, C. Sumpter, K. Ashley, S. Eisen, T. Obrien, M. (2004). Gefitinib in patients with non-small cell lung cancer (NSCLC): The Royal Marsden experience. J clin oncol, Vol.22 (14_suppl), p. 7099.  show abstract

George, A. Riddell, D. Seal, S. Talukdar, S. Mahamdallie, S. Ruark, E. Cloke, V. Slade, I. Kemp, Z. Gore, M. Strydom, A. Banerjee, S. Hanson, H. Rahman, N. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian Cancer Patients. Scientific reports, .  show abstract

Yang, Y. Wu, L. Shu, X. Lu, Y. Shu, X.-. Cai, Q. Beeghly-Fadiel, A. Li, B. Ye, F. Berchuck, A. Anton-Culver, H. Banerjee, S. Benitez, J. Bjørge, L. Brenton, J.D. Butzow, R. Campbell, I.G. Chang-Claude, J. Chen, K. Cook, L.S. Cramer, D.W. DeFazio, A. Dennis, J. Doherty, J.A. Dork, T. Eccles, D.M. Velez Edwards, D. Fasching, P.A. Fortner, R.T. Gayther, S.A. Giles, G.G. Glasspool, R.M. Goode, E.L. Goodman, M.T. Gronwald, J. Harris, H.R. Heitz, F. Hildebrandt, M.A. Høgdall, E. Høgdall, C.K. Huntsman, D.G. Kar, S.P. Karlan, B.Y. Kelemen, L.E. Kiemeney, L.A. Kjaer, S.K. Koushik, A. Lambrechts, D. Le, N.D. Levine, D.A. Massuger, L.F. Matsuo, K. May, T. McNeish, I.A. Menon, U. Modugno, F. Monteiro, A.N. Moorman, P.G. Moysich, K.B. Ness, R.B. Nevanlinna, H. Olsson, H. Onland-Moret, N.C. Park, S.K. Paul, J. Pearce, C.L. Pejovic, T. Phelan, C.M. Pike, M.C. Ramus, S.J. Riboli, E. Rodríguez-Antona, C. Romieu, I. Sandler, D.P. Schildkraut, J.M. Setiawan, V.W. Shan, K. Siddiqui, N. Sieh, W. Stampfer, M.J. Sutphen, R. Swerdlow, A.J. Szafron, L.M. Teo, S.H. Tworoger, S.S. Tyrer, J.P. Webb, P.M. Wentzensen, N. White, E. Willett, W.C. Wolk, A. Woo, Y.L. Wu, A.H. Yan, L. Yannoukakos, D. Chenevix-Trench, G. Sellers, T.A. Pharoah, P.D. Zheng, W. Long, J. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk. Cancer research, , pp. canres.2726.2018-canres.2726.2018.

Porta, N. deSouza, N. Banerjee, S. Yuan, Y. Pace, E. Abdul Jabbar, K. Winfield, J. Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. British journal of cancer, .

Dumas, L. Bowen, R. Butler, J. Banerjee, S. Under-Treatment of Older Patients with Newly Diagnosed Epithelial Ovarian Cancer Remains an Issue. Cancers, Vol.13 (5), pp. 952-952.  show abstract

Horgan, D. Ciliberto, G. Conte, P. Baldwin, D. Seijo, L. Montuenga, L.M. Paz-Ares, L. Garassino, M. Penault-Llorca, F. Galli, F. Ray-Coquard, I. Querleu, D. Capoluongo, E. Banerjee, S. Riegman, P. Kerr, K. Horbach, B. Büttner, R. Van Poppel, H. Bjartell, A. Codacci-Pisanelli, G. Westphalen, B. Calvo, F. Koeva-Balabanova, J. Hall, S. Paradiso, A. Kalra, D. Cobbaert, C. Varea Menendez, R. Maravic, Z. Fotaki, V. Bennouna, J. Cauchin, E. Malats, N. Gutiérrez-Ibarluzea, I. Gannon, B. Mastris, K. Bernini, C. Gallagher, W. Buglioni, S. Kent, A. Munzone, E. Belina, I. Van Meerbeeck, J. Duffy, M. Sarnowska, E. Jagielska, B. Mee, S. Curigliano, G. Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. Biomedicine hub, Vol.5 (3), pp. 1-42.  show abstract

Dumas, L. Lidington, E. Appadu, L. Jupp, P. Husson, O. Banerjee, S. Exploring Older Women’s Attitudes to and Experience of Treatment for Advanced Ovarian Cancer: A Qualitative Phenomenological Study. Cancers, Vol.13 (6), pp. 1207-1207.  show abstract

Fendler, A. Au, L. Boos, L.A. Byrne, F. Shepherd, S.T. Shum, B. Gerard, C.L. Ward, B. Xie, W. Cerrone, M. Cornish, G.H. Pule, M. Mekkaoui, L. Ng, K.W. Stone, R. Gomes, C. Flynn, H.R. Agua-Doce, A. Hobson, P. Caidan, S. Howell, M. Goldstone, R. Gavrielides, M. Nye, E. Snijders, B. Macrae, J. Nicod, J. Hayday, A. Gronthoud, F. Messiou, C. Cunningham, D. Chau, I. Starling, N. Turner, N. Rusby, J. Welsh, L. van As, N. Jones, R. Droney, J. Banerjee, S. Tatham, K. Jhanji, S. O’Brien, M. Curtis, O. Harrington, K. Bhide, S. Slattery, T. Khan, Y. Tippu, Z. Leslie, I. Gennatas, S. Okines, A. Reid, A. Young, K. Furness, A. Pickering, L. Ghandi, S. Gamblin, S. Swanton, C. Nicholson, E. Kumar, S. Yousaf, N. Wilkinson, K. Swerdlow, A. Harvey, R. Kassiotis, G. Wilkinson, R. Larkin, J. Turajlic, S. Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study. , .  show abstract

Khalique, S. Nash, S. Mansfield, D. Wampfler, J. Attygale, A. Vroobel, K. Kemp, H. Buus, R. Cottom, H. Roxanis, I. Jones, T. von Loga, K. Begum, D. Guppy, N. Ramagiri, P. Fenwick, K. Matthews, N. Hubank, M. Lord, C. Haider, S. Melcher, A. Banerjee, S. Natrajan, R. Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma. Cancers, Vol.13 (15), pp. 3854-3854.  show abstract

Lidington, E. Darlington, A.-. Din, A. Stanway, S. Banerjee, S. Szucs, Z. Gonzalez, M. Sharma, A. Sirohi, B. van der Graaf, W.T. Husson, O. Describing Unmet Supportive Care Needs among Young Adults with Cancer (25–39 Years) and the Relationship with Health-Related Quality of Life, Psychological Distress, and Illness Cognitions. Journal of clinical medicine, Vol.10 (19), pp. 4449-4449.  show abstract

Bliss, J. Porta, N. Toms, C. Banerjee, S. Stewart, J. Natrajan, R. Lord, C. ATARI trial: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). International journal of gynecological cancer, .

Fendler, A. Au, L. Shepherd, S. Byrne, F. Cerrone, M. Boos, L. Rzeniewicz, K. Gordon, W. Shum, B. Gerard, C. Ward, B. Xie, W. Schmitt, A. Joharatnam-Hogan, N. Cornish, G. Pule, M. Mekkaoui, L. Ng, K. Carlyle, E. Edmonds, K. Rosario, L.D. Sarker, S. Lingard, K. Mangwende, M. Holt, L. Ahmod, H. Stone, R. Gomes, C. Flynn, H. Agua-Doce, A. Hobson, P. Caidan, S. Howell, M. Wu, M. Goldstone, R. Crawford, M. Cubitt, L. Patel, H. Gavrielides, M. Nye, E. Snijders, A. MacRae, J. Nicod, J. Gronthoud, F. Shea, R. Messiou, C. Cunningham, D. Chau, I. Starling, N. Turner, N. Welsh, L. As, N.V. Jones, R. Droney, J. Banerjee, S. Tatham, K. Jhanji, S. O'Brien, M. Curtis, O. Harrington, K. Bhide, S. Bazin, J. Robinson, A. Stephenson, C. Slattery, T. Khan, Y. Tippu, Z. Leslie, I. Gennatas, S. Okines, A. Reid, A. Young, K. Furness, A. Pickering, L. Gandhi, S. Gamblin, S. Swanton, C. Nicholson, E. Kumar, S. Yousaf, N. Wilkinson, K. Swerdlow, A. Harvey, R. Kassiotis, G. Larkin, J. Wilkinson, R. Turajlic, S. Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. , .  show abstract

Arend, R.C. O’Malley, D.M. Banerjee, S. McLaurin, K. Davidson, R. Long, G.H. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data. Advances in therapy, .


Conferences

Boussios, S.Glaessgen, D.Okines, A.Lalondrelle, S.Taylor, A.McLachlan, J.Gore, M.Kaye, S.Banerjee, S. (2015). 2767 Second line systemic treatment options for recurrent/advanced cervical cancer - The Royal Marsden experience, European Journal of Cancer, Vol.51, p.S553.

Banerjee, S.Ledermann, J.Matulonis, U.Molife, L.R.Friedlander, M.Fielding, A.Robertson, J.D.Spencer, S.McMurtry, E.Kaye, S. (2015). 2759 Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib, European Journal of Cancer, Vol.51, p.S550.

Kolomainen, D.Butler, J.Barton, D.P.Taylor, A.Stanley, K.Gore, M.Banerjee, S. (2015). 2758 Is there a survival benefit for patients who receive post-operative adjuvant chemotherapy following secondary cytoreductive surgery (SCRS) for recurrent epithelial ovarian cancer (EOC)?, European Journal of Cancer, Vol.51, p.S550.

Nicum, S.Boyle, L.Strauss, V.Gourley, C.Hall, M.Montes, A.Abraham, J.Clamp, A.Kennedy, R.Banerjee, S.Roberts, C. (2015). 2761 Phase II clinical trial of 6 mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours, European Journal of Cancer, Vol.51, p.S551.

Rafii, S.Gourley, C.Ang, J.E.Kumar, R.Geuna, E.Rye, T.Ashcroft, L.Powell, B.Shapira-Frommer, R.Friedlander, M.Chen, L.-.Matulonis, U.Kaufman, B.De Greve, J.Oza, A.M.Banerjee, S.N.Gore, M.E.Molife, L.R.Kaye, S.B.Yap, T.A. (2015). What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?, Journal of Clinical Oncology, Vol.33 (15_suppl), p.5546.

Migali, C.Lima, J.P.George, A.Della Pepa, C.Kaye, S.B.Gore, M.E.Banerjee, S. (2014). OVARIAN CARCINOSARCOMA MANAGEMENT: A RETROSPECTIVE ANALYSIS OF THE ROYAL MARSDEN EXPERIENCE, ANNALS OF ONCOLOGY, Vol.25.

George, A.Tunariu, N.Della Pepa, C.Migali, C.Gore, M.Kaye, S.B.Banerjee, S.B. (2013). Response to tamoxifen (T) and letrozole (L) in patients with relapsed high-grade ovarian carcinoma - the Royal Marsden experience, EUROPEAN JOURNAL OF CANCER, Vol.49, p.S732.

McNeish, I.A.Ledermann, J.A.Webber, L.C.James, L.E.Kaye, S.B.Rustin, G.J.Hall, G.Clamp, A.Earl, H.M.Banerjee, S.N.Kristeleit, R.S.Raja, F.Feeney, A.Lawrence, C.Dawson-Athey, L.Persic, M.Khan, I. (2013). A randomized placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer (SaPPrOC), JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

George, A.Tunariu, N.Wilkinson, N.Gupta, S.Gore, M.E.Kaye, S.B.Banerjee, S. (2012). EFFICACY OF PLATINUM PLUS GEMCITABINE (G) IN PLATINUM-RESISTANT (R) COMPARED TO PLATINUM-SENSITIVE (S) OVARIAN CANCER: THE ROYAL MARSDEN EXPERIENCE, ANNALS OF ONCOLOGY, Vol.23, p.320.

Miller, R.Brough, R.Bajrami, I.Kaye, S.Banerjee, S.Lord, C.Ashworth, A. (2012). Functional Profiling of Clear Cell Ovarian Cancer, EUROPEAN JOURNAL OF CANCER, Vol.48, p.33.

Molife, L.R.Mateo, J.McGoldrick, T.Krebs, M.Drew, Y.Banerjee, S.N.Nicum, S.Ranson, M.Rustin, G.J.Sessa, C.Plummer, R.Leunen, K.Friedlander, M.Swaisland, H.Burke, W.McCormack, P.Pemberton, K.Tchakov, I.Kaye, S.B.Gourley, C. (2012). Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations, JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Penson, R.T.Moore, K.N.Fleming, G.F.Braly, P.S.Schimp, V.L.Nguyen, H.Matulonis, U.Banerjee, S.N.Haluska, P.Gore, M.E.Bodurka, D.C.Morozov, A.Xu, Y.Rutstein, M.D.Schwartz, J.D.McGuire, W.P. (2012). A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162)., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Banerjee, S.N.Zvelebil, M.Furet, P.Mueller-Vieira, U.Dowsett, M.Evans, D.Martin, L. (2009). IN VITRO AND IN VIVO STUDIES REVEAL THAT THE VEGF-R INHIBITOR PTK787/ZK222584 IS A COMPETITIVE AROMATASE INHIBITOR, Presented at IMPAKT Breast Cancer Conference 2009, Brussels, BELGIUM. ANNALS OF ONCOLOGY, Vol.20, pp.61-1.

Banerjee, S.N.Thornhill, A.Evans, D.B.Littlewood-Evans, A.J.Dowsett, M.Martin, L.-. (2007). The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy, Presented at 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. BREAST CANCER RESEARCH AND TREATMENT, Vol.106, pp.S8-1.

Banerjee, S.N.Pancholi, S.A'Hern, R.P.Smith, I.E.Dowsett, M.Martin, L.-. (2006). The effect of neo-adjuvant tamoxifen or anastrozole on circulating VEGF levels., Presented at 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. BREAST CANCER RESEARCH AND TREATMENT, Vol.100, pp.S242-1.

Banerjee, S.N.Reis, J.S.Ashley, S.Steele, D.Ashworth, A.Lakhani, S.Smith, I.E. (2005). Basal-like breast carcinomas: clinical outcome with chemotherapy., BREAST CANCER RESEARCH AND TREATMENT, Vol.94, p.S125.

Parton, M.Maisey, N.Banerjee, S.Harper-Wynne, C.Sumpter, K.Ashley, S.Eisen, T.Obrien, M. (2004). Gefitinib in patients with non-small cell lung cancer (NSCLC): The Royal Marsden experience., JOURNAL OF CLINICAL ONCOLOGY, Vol.22 (14), p.641S.

In this section

Research overview Research projects Publications